Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Kerry Group Plc (PK) | USOTC:KRYAY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.08 | 4.37% | 97.50 | 95.33 | 99.05 | 97.50 | 94.91 | 94.92 | 256,342 | 18:22:43 |
From Nov 2023 to Nov 2024
By Christian Moess Laursen
Kerry Group has bought assets from Danish biotechnology companies Novozymes and Chr. Hansen for a total consideration of 150 million euros ($161.5 million).
The deal--expected to close in the first half of 2024--comprises certain trade and assets of Chr. Hansen's global lactase enzyme business and the entire share capital of Nuocheng Trillion Food, a Chinese subsidiary of Novozymes.
The Ireland-based food company said Tuesday that the acquisition improves its ability to create biotechnology solutions following acquisitions of c-LEcta and Enmex in 2022 and 2021, respectively.
It is subject to the European Commission's approval of Kerry as a buyer, and forms part of the Novozymes and Chr. Hansen merger-approval process. Earlier today, the executive arm of the EU conditionally approved the merger.
The assets have attributable revenue around EUR40 million in 2022, with sales in more than 50 countries, Kerry Group said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
December 12, 2023 12:06 ET (17:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Kerry (PK) Chart |
1 Month Kerry (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
